GlaxoSmithKline Is Voluntarily Recalling 593,000 Ventolin Asthma Inhalers

This article was originally published here

British drug maker GlaxoSmithKline (GSK) is voluntarily recalling 593,000 Ventolin asthma inhalers from hospitals, pharmacy, retailers, and wholesalers in the U.S. due to an issue that may cause the inhalers to deliver a lower than intended dose of the medication.

The company had been receiving complaints about a leak of the propellant that delivers the medication, Reuters said. The recall impacts three lots of the inhalers that were manufactured at the company’s GSK plant in Zebulon, North Carolina.

Shares of GSK were up slightly in pre-market trading Wednesday. 

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply